- Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158Wu, X.; Mao, Y.; Xu, N.; Bai, Y.; Wang, D.; Chen, X.; Yin, X.; Deng, Y.; Yang, J.; Zhang, J.; Tang, J.; Huang, Y.; Li, J.; Xu, M.; Li, N.; Mao, Y.; Gozman, A.; Xu, J.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- Pembrolizumab vs chemotherapy in Chinese patients with PD-L1-positive NSCLC: 4-year update from KEYNOTE-042 China studyWu, Yi-Long; Fan, Yun; Zhou, JianYing; Zhang, Li; Zhou, Qing; Li, Wei; Hu, ChengPing; Chen, GongYan; Zhang, Xin; Zhou, CaiCun; Gonzalez Arenas, Carmen; Fu, Wei; Wu, Helen; Mok, TonyAnnual Meeting of the American-Association-for-Cancer-Research (AACR), New Orleans, LA, 2022-04-08 To 2022-04-13.被引 1
- Phase 2 study of tislelizumab monotherapy in previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors: Gynecological cancer subgroupWang, Dong; Zhang, Naiyi; Zang, Aimin; Wang, Jing; Huang, Yi; Shen, Lin; Li, Jian; Zhang, Yanqiao; Liu, Tianshu; Deng, Yanhong; Xu, Yaling; Li, Zhezhen; Wang, Yidi; Gao, Yunong
会议论文
Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
10阅读
